retatrutide phase 2 trial obesity The data just dropped — and is rewriting what's possible in medicine. 🧬 TRIUMPH-1 just released 3 results, and the numbers are unlike anything we've seen from a medication: Retatrutide Safety, Side Effects &

Side effects with different GLP-1 drugs may vary from person to person.

A new Stanford-led study suggests up to 10% of people may be genetically resistant to GLP-1 drugs like Ozempic and Wegovy

Aumento da saciedade

Learn how the CPG manufacturer is addressing the challenges of GLP-1 users and exploring new product offerings.

Heres my small take on the GLP 1 revolution

Today, we announced our investigational glucagon/GLP-1 dual receptor agonist achieved key measures of success at 48 weeks in our IMPACT Phase 2b trial and recent interactions with the FDA have resulted in alignment on the parameters for a registrational Phase 3 trial